文献速递免疫规划慢病防控与筛查卫生政策与健康促进

欧洲9国接受宫颈癌筛查的成年女性HPV疫苗接种意愿与完成度的决定因素

Determinants of Human Papillomavirus Vaccine Uptake by Adult Women Attending Cervical Cancer Screening in 9 European Countries.
PubMed 文献 · Am J Prev Med · 2020-12-24

该干预研究纳入2016年4月至2018年5月在比利时、丹麦、芬兰、法国、德国、斯洛文尼亚、西班牙、瑞典和英国接受机会性或人群筛查的25-45岁女性。参与者填写HPV疫苗接种认知与态度问卷,并受邀免费接种HPV疫苗,主要结局为接种接受度、接种率和3剂程序完成率。结果显示,3646名参与者中2748人接受接种,2151人完成全程;接种接受度与既往知晓成年女性和男性HPV疫苗、招募方式及国家青少年接种覆盖率相关,拒绝主要原因是疫苗安全担忧。

要点

  • 既往知晓成年女性HPV疫苗(OR=1.22,95%CI=1.00,1.48)和男性HPV疫苗(OR=1.59,95%CI=1.28,1.97)与更高接种接受度相关。
  • 稳定关系(OR=0.56,95%CI=0.45,0.69)或更高教育水平(OR=0.76,95%CI=0.63,0.93)的女性更可能拒绝接种。
  • 邮寄邀请相比医疗专业人员当面邀请导致更低接种接受度(OR=0.13,95%CI=0.02,0.76);国家青少年女性接种覆盖率>70%对成年女性HPV疫苗接种的预测呈边缘显著性(OR=3.23,95%CI=0.95,10.97)。

核心结论

  • 成年女性HPV疫苗的接受度和程序完成率在很大程度上取决于招募方式、国家疫苗接种项目达到的覆盖率及个人关系状态。
  • 了解疫苗获益并再次保证安全性可能对扩大疫苗接种目标年龄至关重要。
  • 研究结果提示成年女性对HPV疫苗接种不存在重大意见障碍,尤其是在医疗机构面对面提供接种时。

研究设计与样本

  • 干预研究,纳入2016年4月至2018年5月在9个欧洲国家接受机会性或人群宫颈癌筛查的25-45岁女性。
  • 参与者填写关于成年女性HPV疫苗接种认知与态度的问卷,并受邀免费接种HPV疫苗。
  • 主要结局为接种接受度、接种率和3剂接种程序完成率,采用多水平logistic模型于2019年探索接种决定因素。

主要发现

  • 3646名参与者中2748人(各国范围50%-96%)接受接种,2151人(各国范围30%-93%)完成全程接种。
  • 与更高接种接受度相关的因素包括既往知晓成年女性HPV疫苗(OR=1.22,95%CI=1.00,1.48)和男性HPV疫苗(OR=1.59,95%CI=1.28,1.97)。
  • 稳定关系(OR=0.56,95%CI=0.45,0.69)或更高教育水平(OR=0.76,95%CI=0.63,0.93)的女性更可能拒绝接种。
  • 邮寄邀请相比医疗专业人员个人邀请导致更低接种接受度(OR=0.13,95%CI=0.02,0.76)。
  • 国家公共项目中青少年女孩接种覆盖率>70%对HPV疫苗接种的预测呈边缘显著性(OR=3.23,95%CI=0.95,10.97)。

临床怎么用

  • 在宫颈癌筛查场景中由医疗专业人员面对面邀请并提供免费HPV疫苗接种,可能提高成年女性接种接受度。
  • 针对成年女性开展疫苗获益沟通和安全性再保证,可能有助于扩大HPV疫苗接种目标年龄。
  • 关注稳定关系或高教育水平女性的接种犹豫,并针对安全担忧提供信息。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Human papillomavirus-vaccinated cohorts, irrespective of age, will likely reduce their subsequent screening requirements, thus opening opportunities for global cost reduction and program sustainability. The determinants of uptake and completion of a 3-dose human papillomavirus vaccination program by adult women in a European context were estimated. STUDY DESIGN: This was an intervention study. SETTING/PARTICIPANTS: Study participants were women aged 25-45 years, attending opportunistic or population-based cervical cancer screening in Belgium, Denmark, Finland, France, Germany, Slovenia, Spain, Sweden, and the United Kingdom between April 2016 and May 2018. INTERVENTION: Study participants completed a questionnaire on awareness and attitudes on adult female human papillomavirus vaccination and were invited to receive free human papillomavirus vaccination. MAIN OUTCOME MEASURES: Main outcome measures were acceptance, uptake, and completion of vaccination schedule. Determinants of vaccine uptake were explored using multilevel logistic models in 2019. RESULTS: Among 3,646 participants, 2,748 (range by country=50%-96%) accepted vaccination, and 2,151 (range=30%-93%) received the full vaccination course. The factors associated with higher vaccine acceptance were previous awareness of adult female (OR=1.22, 95% CI=1.00, 1.48) and male (OR=1.59, 95% CI=1.28, 1.97) vaccination. Women in stable relationships (OR=0.56, 95% CI=0.45, 0.69) or with higher educational level (OR=0.76, 95% CI=0.63, 0.93) were more likely to refuse vaccination. Recruitment by postal invitation versus personal invitation from a healthcare professional resulted in lower vaccine acceptance (OR=0.13, 95% CI=0.02, 0.76). Vaccination coverage of >70% of adolescent girls in national public programs was of borderline significance in predicting human papillomavirus vaccine uptake (OR=3.23, 95% CI=0.95, 10.97). The main reasons for vaccine refusal were vaccine safety concerns (range=30%-59%) and the need for more information on human papillomavirus vaccines (range=1%-72%). No safety issues were experienced by vaccinated women. CONCLUSIONS: Acceptance and schedule completion were largely dependent on recruitment method, achieved coverage of national vaccination programs, and personal relationship status. Knowledge of benefits and safety reassurance may be critical to expanding vaccination target ages. Study results suggest that there are no major opinion barriers in adult women to human papillomavirus vaccination, especially when vaccination is offered face to face in healthcare settings. TRIAL REGISTRATION: EudraCT Number 2014-003177-42.

来源:Am J Prev Med,查看原文。版权归原作者所有。

引用

  1. Robles C, Bruni L, Acera A, et al. Determinants of Human Papillomavirus Vaccine Uptake by Adult Women Attending Cervical Cancer Screening in 9 European Countries. Am J Prev Med. 2020. PMID: 33358719. doi:10.1016/j.amepre.2020.08.032

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。